Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Samuel Urrutia

Samuel Urrutia

MD
Washington University School of Medicine
Understanding the drivers of resistance in AML in order to improve targeted therapy 1:25
Understanding the drivers of resistance in AML in order to improve targeted therapy
Samuel Urrutia • 8 Dec 2024
Comparing the IPSS-M and IPSS-R for risk stratification of patients with MDS & spliceosome mutations 1:30
Comparing the IPSS-M and IPSS-R for risk stratification of patients with MDS & spliceosome mutations
Samuel Urrutia • 8 Dec 2024
A propensity score matching analysis evaluating oral decitabine/cedazuridine in TP53-mutated MDS 1:42
A propensity score matching analysis evaluating oral decitabine/cedazuridine in TP53-mutated MDS
Samuel Urrutia • 8 Dec 2024
IPSS-M: prognostic power in HMA-treated MDS patients 1:35
IPSS-M: prognostic power in HMA-treated MDS patients
Samuel Urrutia • 9 Dec 2023
The challenge of treating HMA-refractory MDS patients 1:04
The challenge of treating HMA-refractory MDS patients
Samuel Urrutia • 9 Dec 2023
Guadecitabine in higher-risk MDS/CMML: a Phase II trial 1:46
Guadecitabine in higher-risk MDS/CMML: a Phase II trial
Samuel Urrutia • 9 Dec 2023
The content of VJHemOnc is intended for healthcare professionals